Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

LTR Pharma Taps Nick Bell to Support Digital Health and Commercial Growth

LTP: $0.410 +0.00% · MC: $86M

LTR Pharma has appointed entrepreneur Nick Bell as a strategic adviser, with an initial focus on introductions to telehealth platforms, clinic networks and commercial partners. He will also help evaluate scalable, compliant patient-access pathways for SPONTAN and KYZATREX in Australia; the appointment is intended to strengthen the company’s digital-health and commercial capabilities.

Source announcements: 2026-11-04 08:22 to 2026-11-04 08:22 Sydney time
Story updated 2026-11-04 08:40 Sydney time
SourcesNick Bell Joins LTR Pharma as Strategic Adviser
Comments